News

Univercells, an innovative bioprocessing provider focused on increasing the availability of affordable biologics to address global health challenges, has announced up to EUR 50M…
Read More...

GlaxoSmithKline announced that the U.S. Food and Drug Administration (FDA) has approved Voltaren Arthritis Pain (diclofenac sodium topical gel, 1% (NSAID)- arthritis pain reliever) as…
Read More...

Novartis announced the European Commission (EC) has approved Beovu (brolucizumab) injection for the treatment of wet age-related macular degeneration (AMD). Beovu is the first…
Read More...

Ascletis Pharma Inc. announces the application for in-house developed Category 1 Drug ASC41 for clinical trials of NASH indication has been accepted by China's National Medical Products…
Read More...

GlaxoSmithKline announced that the U.S. Food and Drug Administration (FDA) has approved Voltaren Arthritis Pain (diclofenac sodium topical gel, 1% (NSAID)- arthritis pain reliever) as…
Read More...

PharmaMar and Jazz Pharmaceuticals plc announce that the U.S. Food and Drug Administration (FDA) accepted for filing with Priority Review the New Drug Application (NDA) seeking…
Read More...

Zydus Cadila, an innovation-driven, global pharmaceutical company, announced that it has initiated an accelerated research programme with multiple teams in India and Europe developing a…
Read More...

PCI Pharma Services (PCI) announced the acquisition of Bellwyck Pharma Services (Bellwyck), headquartered in Toronto, Canada. With 25 years of experience, Bellwyck is a leader in…
Read More...

Seattle Genetics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Company’s New Drug Application (NDA) for the investigational…
Read More...

Soligenix, Inc. announced that its RiVax (heat stable ricin toxin vaccine) development program for prevention of ricin intoxication has received "Fast Track" designation from the US…
Read More...

Vir Biotechnology, Inc. a clinical-stage immunology company focused on immune approaches to treating and preventing serious infectious diseases, announced that it has identified two…
Read More...

Comar, a specialty packaging, device, and component supplier serving the Medical, Pharmaceutical, Consumer Healthcare, Personal and Home Care, Food and Beverage, and other niche market…
Read More...

Merck, known as MSD outside the United States and Canada, announced that the pivotal Phase 3 KEYNOTE-355 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with…
Read More...

OSE Immunotherapeutics announced a new collaboration agreement with deep technology innovative start-up MAbSilico, located in Tours, France, to use artificial intelligence (AI)-based…
Read More...

Dr. Reddy’s Laboratories Ltd. announced that it has entered into a definitive agreement with Wockhardt Limited to acquire select divisions of its branded generics business in India and…
Read More...

ALX Oncology announced the closing of a $105 million Series C equity financing. Vivo Capital was the lead investor with other new investors including funds managed by Logos Capital,…
Read More...

Novartis announced that the US Food and Drug Administration (FDA) accepted and granted Priority Review to capmatinib’s (INC280) New Drug Application (NDA). Capmatinib is a MET inhibitor…
Read More...

Cannabics Pharmaceuticals Inc. announced that it has signed a Memorandum Of Understanding with RCK Medical Cannabis to develop cannabis chemovars targeted to treat gastro intestinal…
Read More...

Astellas Pharma Inc. and Pfizer Inc. announced results of the final overall survival (OS) analysis from the Phase 3 PROSPER trial, which evaluated XTANDI (enzalutamide) plus androgen…
Read More...

Bayer AG announced that it entered into a definitive agreement to transfer a large part of its Berlin-based small molecule research unit to Nuvisan, an international service provider…
Read More...